127 related articles for article (PubMed ID: 38417401)
21. Targeting NPRL2 to enhance the efficacy of Olaparib in castration-resistant prostate cancer.
Chen X; Chen Z; Zheng B; Tang W
Biochem Biophys Res Commun; 2019 Jan; 508(2):620-625. PubMed ID: 30522863
[TBL] [Abstract][Full Text] [Related]
22. Anti-oncogenic mechanism of KLF17 in colon cancer by repressing cell migration and invasion via FHL1 upregulation.
Yi S; Luo M; Peng Y; Chen Y; Yu D
Chin J Physiol; 2023; 66(6):534-545. PubMed ID: 38149566
[TBL] [Abstract][Full Text] [Related]
23. Alisertib, an Aurora kinase A inhibitor, induces apoptosis and autophagy but inhibits epithelial to mesenchymal transition in human epithelial ovarian cancer cells.
Ding YH; Zhou ZW; Ha CF; Zhang XY; Pan ST; He ZX; Edelman JL; Wang D; Yang YX; Zhang X; Duan W; Yang T; Qiu JX; Zhou SF
Drug Des Devel Ther; 2015; 9():425-64. PubMed ID: 25624750
[TBL] [Abstract][Full Text] [Related]
24. Olaparib induced senescence under P16 or P53 dependent manner in ovarian cancer.
Wang Z; Gao J; Zhou J; Liu H; Xu C
J Gynecol Oncol; 2019 Mar; 30(2):e26. PubMed ID: 30740957
[TBL] [Abstract][Full Text] [Related]
25. Proguanil synergistically sensitizes ovarian cancer cells to olaparib by increasing DNA damage and inducing apoptosis.
Wu Y; Wu T; Hu X; Xu S; Xiao D; Wu J; Yan X; Yang X; Li G
Int J Med Sci; 2022; 19(2):233-241. PubMed ID: 35165509
[TBL] [Abstract][Full Text] [Related]
26. Genistein suppressed epithelial-mesenchymal transition and migration efficacies of BG-1 ovarian cancer cells activated by estrogenic chemicals via estrogen receptor pathway and downregulation of TGF-β signaling pathway.
Kim YS; Choi KC; Hwang KA
Phytomedicine; 2015 Oct; 22(11):993-9. PubMed ID: 26407941
[TBL] [Abstract][Full Text] [Related]
27. miR-636 inhibits EMT, cell proliferation and cell cycle of ovarian cancer by directly targeting transcription factor Gli2 involved in Hedgehog pathway.
Ma J; Zhou C; Chen X
Cancer Cell Int; 2021 Jan; 21(1):64. PubMed ID: 33472614
[TBL] [Abstract][Full Text] [Related]
28. Augmentation of response to chemotherapy by microRNA-506 through regulation of RAD51 in serous ovarian cancers.
Liu G; Yang D; Rupaimoole R; Pecot CV; Sun Y; Mangala LS; Li X; Ji P; Cogdell D; Hu L; Wang Y; Rodriguez-Aguayo C; Lopez-Berestein G; Shmulevich I; De Cecco L; Chen K; Mezzanzanica D; Xue F; Sood AK; Zhang W
J Natl Cancer Inst; 2015 Jul; 107(7):. PubMed ID: 25995442
[TBL] [Abstract][Full Text] [Related]
29. HPIP promotes epithelial-mesenchymal transition and cisplatin resistance in ovarian cancer cells through PI3K/AKT pathway activation.
Bugide S; Gonugunta VK; Penugurti V; Malisetty VL; Vadlamudi RK; Manavathi B
Cell Oncol (Dordr); 2017 Apr; 40(2):133-144. PubMed ID: 28039608
[TBL] [Abstract][Full Text] [Related]
30. MiR-509-3 augments the synthetic lethality of PARPi by regulating HR repair in PDX model of HGSOC.
Sun C; Cao W; Qiu C; Li C; Dongol S; Zhang Z; Dong R; Song K; Yang X; Zhang Q; Kong B
J Hematol Oncol; 2020 Jan; 13(1):9. PubMed ID: 32005272
[TBL] [Abstract][Full Text] [Related]
31. Entinostat, a selective HDAC1/2 inhibitor, potentiates the effects of olaparib in homologous recombination proficient ovarian cancer.
Gupta VG; Hirst J; Petersen S; Roby KF; Kusch M; Zhou H; Clive ML; Jewell A; Pathak HB; Godwin AK; Wilson AJ; Crispens MA; Cybulla E; Vindigni A; Fuh KC; Khabele D
Gynecol Oncol; 2021 Jul; 162(1):163-172. PubMed ID: 33867143
[TBL] [Abstract][Full Text] [Related]
32. BRCA Status Does Not Predict Synergism of a Carboplatin and Olaparib Combination in High-Grade Serous Ovarian Cancer Cell Lines.
Shen YT; Evans JC; Zafarana G; Allen C; Piquette-Miller M
Mol Pharm; 2018 Jul; 15(7):2742-2753. PubMed ID: 29750868
[TBL] [Abstract][Full Text] [Related]
33. Targeted inhibition of the ATR/CHK1 pathway overcomes resistance to olaparib and dysregulates DNA damage response protein expression in BRCA2
Biegała Ł; Gajek A; Szymczak-Pajor I; Marczak A; Śliwińska A; Rogalska A
Sci Rep; 2023 Dec; 13(1):22659. PubMed ID: 38114660
[TBL] [Abstract][Full Text] [Related]
34. Celecoxib induces epithelial-mesenchymal transition in epithelial ovarian cancer cells via regulating ZEB1 expression.
Liu R; Zheng J; Li C; Pang Y; Zheng Q; Xu X; Liu P
Arch Gynecol Obstet; 2015 Jun; 291(6):1361-9. PubMed ID: 25424898
[TBL] [Abstract][Full Text] [Related]
35. Dictamnine promotes apoptosis and inhibits epithelial-mesenchymal transition, migration, invasion and proliferation by downregulating the HIF-1α and Slug signaling pathways.
Wang JY; Wang Z; Li MY; Zhang Z; Mi C; Zuo HX; Xing Y; Wu YL; Lian LH; Xu GH; Piao LX; Ma J; Jin X
Chem Biol Interact; 2018 Dec; 296():134-144. PubMed ID: 30266538
[TBL] [Abstract][Full Text] [Related]
36. Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), enhances anti-tumor effects of the poly (ADP-ribose) polymerase (PARP) inhibitor olaparib in triple-negative breast cancer cells.
Min A; Im SA; Kim DK; Song SH; Kim HJ; Lee KH; Kim TY; Han SW; Oh DY; Kim TY; O'Connor MJ; Bang YJ
Breast Cancer Res; 2015 Mar; 17():33. PubMed ID: 25888415
[TBL] [Abstract][Full Text] [Related]
37. MiR-200c sensitizes Olaparib-resistant ovarian cancer cells by targeting Neuropilin 1.
Vescarelli E; Gerini G; Megiorni F; Anastasiadou E; Pontecorvi P; Solito L; De Vitis C; Camero S; Marchetti C; Mancini R; Benedetti Panici P; Dominici C; Romano F; Angeloni A; Marchese C; Ceccarelli S
J Exp Clin Cancer Res; 2020 Jan; 39(1):3. PubMed ID: 31898520
[TBL] [Abstract][Full Text] [Related]
38. Silibinin exerts anti-cancer activity on human ovarian cancer cells by increasing apoptosis and inhibiting epithelial-mesenchymal transition (EMT).
Maleki N; Yavari N; Ebrahimi M; Faisal Faiz A; Khosh Ravesh R; Sharbati A; Panji M; Lorian K; Gravand A; Abbasi M; Abazari O; Shafiee Mehr M; Eskandari Y
Gene; 2022 May; 823():146275. PubMed ID: 35189245
[TBL] [Abstract][Full Text] [Related]
39. GnRH-R-Targeted Lytic Peptide Sensitizes
Ma S; Pradeep S; Villar-Prados A; Wen Y; Bayraktar E; Mangala LS; Kim MS; Wu SY; Hu W; Rodriguez-Aguayo C; Leuschner C; Liang X; Ram PT; Schlacher K; Coleman RL; Sood AK
Mol Cancer Ther; 2019 May; 18(5):969-979. PubMed ID: 30926640
[TBL] [Abstract][Full Text] [Related]
40. Reduction of metastatic potential by inhibiting EGFR/Akt/p38/ERK signaling pathway and epithelial-mesenchymal transition after carbon ion exposure is potentiated by PARP-1 inhibition in non-small-cell lung cancer.
Chowdhury P; Dey P; Ghosh S; Sarma A; Ghosh U
BMC Cancer; 2019 Aug; 19(1):829. PubMed ID: 31438892
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
